© 2005 Oxford University Press
ARTICLE |
Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy
on behalf of the Swiss HIV Cohort Study,
Affiliations of authors: International Agency for Research on Cancer, Lyon, France (GMC, SF); Centro di Riferimento Oncologico, Aviano, Italy (JP, LDM); Coordination and Data Centre, Swiss HIV Cohort Study, Lausanne, Switzerland (MR, OK); Cancer Registry of the Canton of Zürich, Zürich, Switzerland (AK); 5Cancer Registry of the Canton of Geneva, Geneva, Switzerland (ER); Cancer Registry of the Canton of Vaud, Lausanne, Switzerland (FL); Cancer Registry of the Canton of Neuchâtel, Neuchâtel, Switzerland (FL); Cancer Registry of Basel, Basel, Switzerland (GJ); Cancer Registry of St. Gallen and Appenzell, St. Gallen, Switzerland (TF); Cancer Registry of the Canton of Ticino, Locarno, Switzerland (AB); Cancer Registry of the Canton of Valais, Sion, Switzerland (DDW)
Correspondence to: Gary M. Clifford, Ph.D., International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France (e-mail: clifford{at}iarc.fr).
Background: Persons infected with human immunodeficiency virus (HIV) have an increased risk for several cancers, but the influences of behavioral risk factors, such as smoking and intravenous drug use, and highly active antiretroviral therapy (HAART) on cancer risk are not clear. Methods: Patient records were linked between the Swiss HIV Cohort Study and Swiss cantonal cancer registries. Observed and expected numbers of incident cancers were assessed in 7304 persons infected with HIV followed for 28 836 person-years. Relative risks for cancer compared with those for the general population were determined by estimating cancer registry–, sex-, age-, and period-standardized incidence ratios (SIRs). Results: Highly elevated SIRs were confirmed in persons infected with HIV for Kaposi sarcoma (KS) (SIR = 192, 95% confidence interval [CI] = 170 to 217) and non-Hodgkin lymphoma (SIR = 76.4, 95% CI = 66.5 to 87.4). Statistically significantly elevated SIRs were also observed for anal cancer (SIR = 33.4, 95% CI = 10.5 to 78.6); Hodgkin lymphoma (SIR = 17.3, 95% CI = 10.2 to 27.4); cancers of the cervix (SIR = 8.0, 95% CI = 2.9 to 17.4); liver (SIR = 7.0, 95% CI = 2.2 to 16.5); lip, mouth, and pharynx (SIR = 4.1, 95% CI = 2.1 to 7.4); trachea, lung, and bronchus (SIR = 3.2, 95% CI = 1.7 to 5.4); and skin, nonmelanomatous (SIR = 3.2, 95% CI = 2.2 to 4.5). In HAART users, SIRs for KS (SIR = 25.3, 95% CI = 10.8 to 50.1) and non-Hodgkin lymphoma (SIR = 24.2, 95% CI = 15.0 to 37.1) were lower than those for nonusers (KS SIR = 239, 95% CI = 211 to 270; non-Hodgkin lymphoma SIR = 99.3, 95% CI = 85.8 to 114). Among HAART users, however, the SIR (although not absolute numbers) for Hodgkin lymphoma (SIR = 36.2, 95% CI = 16.4 to 68.9) was comparable to that for KS and non-Hodgkin lymphoma. No clear impact of HAART on SIRs emerged for cervical cancer or non–acquired immunodeficiency syndrome-defining cancers. Cancers of the lung, lip, mouth, or pharynx were not observed among nonsmokers. Conclusion: In persons infected with HIV, HAART use may prevent most excess risk of KS and non-Hodgkin lymphoma, but not that of Hodgkin lymphoma and other non–acquired immunodeficiency syndrome-defining cancers. No cancers of the lip, mouth, pharynx, or lung were observed in nonsmokers.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome and Cancer: Past, Present, and Future
- Eric A. Engels and James J. Goedert
J Natl Cancer Inst 2005 97: 407-409.[Extract] [Full Text] [PDF]
Related Memo to the Media
- Press Release: Antiretroviral Therapy May Prevent Excess Risk of Some Cancers in People With HIV
- Sarah L. Zielinski
J Natl Cancer Inst 2005 97: 405.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  J.-P. Spano, D. Costagliola, C. Katlama, N. Mounier, E. Oksenhendler, and D. Khayat AIDS-Related Malignancies: State of the Art and Therapeutic Challenges J. Clin. Oncol., October 10, 2008; 26(29): 4834 - 4842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Battegay, J. Fehr, U. Fluckiger, and L. Elzi Antiretroviral therapy of late presenters with advanced HIV disease J. Antimicrob. Chemother., July 1, 2008; 62(1): 41 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Denny, R. Boa, A.-L. Williamson, B. Allan, D. Hardie, R. Stan, and L. Myer Human Papillomavirus Infection and Cervical Disease in Human Immunodeficiency Virus-1-Infected Women Obstet. Gynecol., June 1, 2008; 111(6): 1380 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Patel, D. L. Hanson, P. S. Sullivan, R. M. Novak, A. C. Moorman, T. C. Tong, S. D. Holmberg, J. T. Brooks, and for the Adult and Adolescent Spectrum of Disease P Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992-2003 Ann Intern Med, May 20, 2008; 148(10): 728 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Kim, S. J. Kim, J.-S. Kim, E. S. Kim, H.-J. Shin, J. S. Chung, Y.-H. Min, M. H. Lee, Y. J. Choi, S.-M. Bang, et al. Report of Aids-related Lymphoma in South Korea Jpn. J. Clin. Oncol., February 8, 2008; (2008) hym168v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Y. Chiao, T. P. Giordano, P. Richardson, and H. B. El-Serag Human Immunodeficiency Virus-Associated Squamous Cell Cancer of the Anus: Epidemiology and Outcomes in the Highly Active Antiretroviral Therapy Era J. Clin. Oncol., January 20, 2008; 26(3): 474 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Chan and J. S. Berek Impact of the Human Papilloma Vaccine on Cervical Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2975 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Biggar, A. K. Chaturvedi, J. J. Goedert, and E. A. Engels AIDS-Related Cancer and Severity of Immunosuppression in Persons With AIDS J Natl Cancer Inst, June 20, 2007; 99(12): 962 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Stebbing, A. Sanitt, A. Teague, T. Powles, M. Nelson, B. Gazzard, and M. Bower Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma J. Clin. Oncol., June 1, 2007; 25(16): 2230 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Fossa, E. Gilbert, G. M. Dores, J. Chen, K. A. McGlynn, S. Schonfeld, H. Storm, P. Hall, E. Holowaty, A. Andersen, et al. Noncancer Causes of Death in Survivors of Testicular Cancer J Natl Cancer Inst, April 4, 2007; 99(7): 533 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Grulich, C. M. Vajdic, and W. Cozen Altered Immunity as a Risk Factor for Non-Hodgkin Lymphoma Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 405 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Biggar, E. S. Jaffe, J. J. Goedert, A. Chaturvedi, R. Pfeiffer, E. A. Engels, and for the HIV/AIDS Cancer Match Study Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS Blood, December 1, 2006; 108(12): 3786 - 3791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Cadranel, D Garfield, A Lavole, M Wislez, B Milleron, and C Mayaud Lung cancer in HIV infected patients: facts, questions and challenges. Thorax, November 1, 2006; 61(11): 1000 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Bini, J. Park, and F. Francois Use of Flexible Sigmoidoscopy to Screen for Colorectal Cancer in HIV-Infected Patients 50 Years of Age and Older. Arch Intern Med, August 14, 2006; 166(15): 1626 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bower, T. Powles, M. Nelson, S. Mandalia, B. Gazzard, and J. Stebbing Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst, August 2, 2006; 98(15): 1088 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grabar, B. Abraham, A. Mahamat, P. Del Giudice, E. Rosenthal, and D. Costagliola Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement J. Clin. Oncol., July 20, 2006; 24(21): 3408 - 3414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Altieri, F. Castro, J. L. Bermejo, and K. Hemminki Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1281 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bower, D. Mazhar, and J. Stebbing Should Cervical Cancer Be an Acquired Immunodeficiency Syndrome-Defining Cancer? J. Clin. Oncol., June 1, 2006; 24(16): 2417 - 2419. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hentrich, L. Maretta, K. U. Chow, J. R. Bogner, D. Schurmann, P. Neuhoff, H. Jager, D. Reichelt, M. Vogel, M. Ruhnke, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study Ann. Onc., June 1, 2006; 17(6): 914 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Combs, N. Neil, and D. M. Aboulafia Liposomal Doxorubicin, Cyclophosphamide, and Etoposide and Antiretroviral Therapy for Patients with AIDS-Related Lymphoma: A Pilot Study. Oncologist, June 1, 2006; 11(6): 666 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Lillo and C. Uberti-Foppa Human papillomavirus viral load: a possible marker for cervical disease in HIV-infected women J. Antimicrob. Chemother., May 1, 2006; 57(5): 810 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Engels, M. V. Brock, J. Chen, C. M. Hooker, M. Gillison, and R. D. Moore Elevated Incidence of Lung Cancer Among HIV-Infected Individuals J. Clin. Oncol., March 20, 2006; 24(9): 1383 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grabar, L. Weiss, and D. Costagliola HIV infection in older patients in the HAART era J. Antimicrob. Chemother., January 1, 2006; 57(1): 4 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Masur Management of Patients with HIV in the Intensive Care Unit. Proceedings of the ATS, January 1, 2006; 3(1): 96 - 102. [Abstract] [Full Text] [PDF]
|
|